Ipragliflozin treatment for 24 weeks did not significantly improve left ventricular diastolic function (E/e') compared with conventional treatment in patients with T2D and HFpEF (P=0.95).
RCT (n=68)
Open-label
randomly assigned
Yes
Does ipragliflozin improve left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction?
In patients with type 2 diabetes and heart failure with preserved ejection fraction, 24 weeks of ipragliflozin treatment did not significantly improve left ventricular diastolic function compared with conventional treatment.
Absolute Event Rate: 10.4% vs 10.1%
p-value: p=0.95
AIM: We carried out a randomized controlled trial using ipragliflozin. We analyzed changes in diastolic function using echocardiography in patients with type 2 diabetes and heart failure with preserved ejection fraction. METHODS: We carried out an open-label, multicenter, randomized, two-arm interventional trial. A total of eligible 68 participants were randomly assigned into two groups (ipragliflozin group n = 36; conventional treatment group n = 32). Primary end-points were the change in E/e' and e'. Secondary end-points were other parameters of echocardiography, plasma NT-proBNP level, New York Heart Association class, hemoglobin A1c and blood pressure. RESULTS: After 24 weeks of follow up, E/e' decreased in both groups (ipragliflozin: 11.0 vs 10.4; conventional treatment 10.5 vs 10.1; multivariate-adjusted P = 0.95). There were no significant differences in the amount of change in E/e', e', echocardiography parameters, plasma NT-proBNP level, New York Heart Association class, hemoglobin A1c and blood pressure between the two groups. In the subgroup analysis, ipragliflozin treatment decreased in left ventricular mass index in patients aged ≥70 years and also decreased in NT-proBNP levels in patients with baseline NT-proBNP ≥400 pg/mL. CONCLUSIONS: In this randomized controlled study carried out in patients with type 2 diabetes and heart failure with preserved ejection fraction, 24-week ipragliflozin treatment did not improve left ventricular diastolic function compared with conventional treatment. As the subgroup, ipragliflozin treatment decreased in left ventricular mass index in participants aged ≥70 years. Geriatr Gerontol Int 2022; 22: 298-304.
Akasaka et al. (2022) conducted an RCT in type 2 diabetes and heart failure with preserved ejection fraction (n=68). ipragliflozin vs. conventional treatment was evaluated on change in E/e' and e' (p=0.95). Ipragliflozin treatment for 24 weeks did not significantly improve left ventricular diastolic function (E/e') compared with conventional treatment in patients with T2D and HFpEF (P=0.95).